HJRES74-119

In Committee

Disapproving the rule submitted by the Bureau of Consumer Financial Protection relating to "Prohibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V)".

119th Congress Introduced Mar 6, 2025

Summary

What This Bill Does

H.J.Res.74 is a Congressional Review Act disapproval resolution. It targets the Consumer Financial Protection Bureau rule relating to Regulation V prohibition on creditors and consumer reporting agencies using medical information and provides that the rule shall have no force or effect. The targeted rule restricts creditor and consumer-reporting use of medical information in credit decisions and credit files. The practical result is not a new replacement rule; it is a congressional veto of the agency action, which can also restrict the agency from issuing a substantially similar rule without new statutory authority.

Who Benefits and How

Creditors using medical information benefit because disapproval would remove or prevent the regulatory obligations created by the rule. Members of Congress opposing the rule benefit because the CRA provides a direct vehicle to nullify the agency action. Regulated parties benefit from clearer congressional opposition to the rule and less near-term implementation risk. Consumer reporting agencies benefit if disapproval prevents new medical-information restrictions in credit reporting.

Who Bears the Burden and How

Consumer Financial Protection Bureau rulemaking staff must respond to congressional disapproval and may be constrained from issuing a substantially similar rule. Consumers with medical debt bear the burden if protections, standards, or program changes in the rule are blocked. Congressional oversight committees must handle the policy consequences of removing the rule without passing a replacement. Patients may lose protection against medical information affecting credit access or credit reports.

Key Provisions

  • Provides congressional disapproval of the Consumer Financial Protection Bureau rule relating to Regulation V prohibition on creditors and consumer reporting agencies using medical information.
  • Blocks the rule by declaring that it shall have no force or effect.
  • Uses the Congressional Review Act rather than ordinary notice-and-comment rulemaking.
  • Restricts the agency's ability to issue a substantially similar rule unless Congress authorizes it.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.

At a Glance

What This Bill Does

Uses the Congressional Review Act to disapprove the Consumer Financial Protection Bureau rule relating to Regulation V prohibition on creditors and consumer reporting agencies using medical information, causing that rule to have no force or effect.

Key Policy Areas

Administrative Law, Congressional Review Act

Primary Purpose

Uses the Congressional Review Act to disapprove the Consumer Financial Protection Bureau rule relating to Regulation V prohibition on creditors and consumer reporting agencies using medical information, causing that rule to have no force or effect.

Policy Domains

Administrative Law Congressional Review Act

Resolution provisions

Identified Gains
Contextual inference, no direct clause citation
  • Creditors using medical information
  • Members of Congress opposing the rule
  • Regulated parties
  • Congressional oversight committees
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih

Contextual inference, no direct clause citation

Identified Costs
Contextual inference, no direct clause citation
  • Consumer Financial Protection Bureau rulemaking staff
  • Consumers with medical debt
  • Congressional oversight committees
  • Program administrators
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih

Contextual inference, no direct clause citation

Legislative Progress

In Committee
Introduced Committee Passed
Mar 6, 2025

Referred to the House Committee on Financial Services.

Mar 6, 2025

Introduced in House

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Consumers
2 mentions across 1 clause
+1 positive -1 negative

Consumer reporting agencies, Patients seeking credit

Positive-direction: Consumer reporting agencies

Negative-direction: Patients seeking credit

Financial Services
1 mention across 1 clause
+1 positive

Creditors using medical information

Healthcare
1 mention across 1 clause
-1 negative

Consumers with medical debt

1/1
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Administrative Law Congressional Review Act

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology